Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial - De Botton, S; Risueño, A; Schuh, AC; Lowenberg, B; Kim, H-J; Vyas, P; Wei, AH; Stein, EM; Dohner, H; Fathi, AT; Dinardo, CD; Martin Regueira, P; et al. (American Society of Clinical Oncology, 2022)